US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
20.11
+0.16 (+0.80%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ACADIA Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
September 28, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial
↗
September 24, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with...
Via
MarketBeat
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
September 24, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA Pharmaceuticals (NASDAQ:ACAD) Displays High Growth Momentum and a Breakout Setup
↗
August 31, 2026
Via
Chartmill
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance
↗
August 04, 2026
Via
Chartmill
Topics
Earnings
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
August 24, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data
↗
August 12, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s...
Via
MarketBeat
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand.
Via
The Motley Fool
Topics
Earnings
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower
↗
May 06, 2026
Via
Chartmill
Topics
Earnings
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
↗
August 04, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and...
Via
MarketBeat
Topics
Earnings
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 04, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 30, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
July 20, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
July 15, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
↗
July 11, 2026
Acadia Pharmaceuticals specializes in CNS therapies; a key insider recently trimmed their stake amid ongoing product pipeline developments.
Via
The Motley Fool
Topics
Regulatory Compliance
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
July 06, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Why Acadia Pharmaceuticals Stock Is Soaring Today
↗
June 26, 2026
An approval of one of its drugs for a major market is now looking likely.
Via
The Motley Fool
Traders are paying attention to the gapping stocks in Friday's session.
↗
June 26, 2026
Via
Chartmill
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
↗
June 26, 2026
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc...
Via
Benzinga
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
June 26, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth
↗
May 19, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide...
Via
MarketBeat
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
↗
May 12, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders,...
Via
MarketBeat
Acadia (ACAD) Q1 2026 Earnings Transcript
↗
May 06, 2026
Acadia (ACAD) Q1 2026 Earnings Transcript
Via
The Motley Fool
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
May 06, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
April 30, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
April 28, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
April 17, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
April 15, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...
Via
MarketMinute
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
